NCT00388349

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Gemcitabine and High-dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 146 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease

Detailed description

To assess the non-hematologic toxicity and determine the phase 2 dose of gemcitabine in combination with vinorelbine followed by carmustine, etoposide and cyclophosphamide and autologous hematopoietic stem cell transplantation \[aka peripheral blood stem cell (PBSC)\].

Conditions

• Hodgkin Disease
• Hodgkin's Lymphoma
• Lymphoma

Interventions

Type	Name	Description
DRUG	Gemcitabine
DRUG	Vinorelbine
DRUG	Carmustine
DRUG	Etoposide
DRUG	Cyclophosphamide
PROCEDURE	Autologous HCT

Timeline

• Start date: 2001-09-01
• Primary completion: 2008-03-01
• Completion: 2010-09-01
• First posted: 2006-10-16
• Last updated: 2017-06-14
• Results posted: 2017-06-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study